TCRX TScan Therapeutics, Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

$6.62  -0.40 (-5.70%)
As of 12/02/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/16/2021
Outstanding shares:  18,624,902
Average volume:  17,826
Market cap:   $130,746,812
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    89854M101
ISIN:        US89854M1018
Valuation   (See tab for details)
PE ratio:   -3.58
PB ratio:   0.90
PS ratio:   16.18
Return on equity:   -24.26%
Net income %:   -522.54%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy